The offering provides necessary capital for late-stage trials and potential NDA submission, but the dilution and insider selling are near-term negatives. Watch for the stock's reaction at open and any further insider transactions. The next major catalyst is CHAPTER-3 topline data in Q3 2026.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $30.09entry
- T+1 · 6mo ago −0.47%α −0.70% · $29.95
- T+5 · 6mo ago +2.03%α +0.56% · $30.70
- T+20 · 5mo ago +3.32%α +3.30% · $31.09
- T+60 · 3mo ago +12.56%α +7.72% · $33.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6% dilution. The capital raise funds late-stage HAE/AAE programs, but recent insider selling ($1.8M in 30 days) and dilution create near-term headwinds. The offering closes May 11, 2026.
Key Financial Metrics
Key Facts
- Priced 3,874,664 ordinary shares at $29.68 per share for gross proceeds of ~$115M
- Underwriters have a 30-day option for up to 581,199 additional shares
- Offering expected to close on or about May 11, 2026
- Joint book-running managers: Morgan Stanley, Leerink Partners, Cantor, Wells Fargo Securities
- Proceeds to fund clinical development and potential commercialization of deucrictibant for HAE and AAE-C1INH
- Recent insider selling: 4 transactions totaling $1.8M in the past 30 days
Financial Impact
~6-7% dilution based on ~64M shares outstanding implied by $1.9B market cap at $29.68; gross proceeds of $115M
Risk Factors
- Dilution of ~6-7% reduces EPS and ownership for existing shareholders
- Insider selling ahead of offering may signal lack of confidence
- Clinical trial risks for deucrictibant (HAE/AAE programs)
- Regulatory approval uncertainty for NDA submission planned in H1 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290920 |
Track record
51 reports on PHVS
15 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers